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Abstract 
The increasing devolution of healthcare towards community care has meant that the management of 
many conditions is conducted within the home either by community nurses or by the patients 
themselves. The administration of medicines within home health care scenarios can however be 
problematic – especially when considering the delivery of medicines through injection. The possibility 
of needlestick injury (NSI) has become an ever-present hazard within healthcare settings with a 
significant proportion of percutaneous injuries occurring during the handling and disposal of the 
needle. The emergence of transdermal microneedle systems however offers a potentially 
revolutionary advance and could dramatically improve safety – particularly within home health care 
where there are mounting concerns over the use and disposal of sharps.  A mini-review of the 
advantages proffered by microneedle drug delivery technologies is presented and the potential 
impact on delivery of medicines within the home  is critically appraised. 
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1.0 Introduction 
Hypodermic injection is an invaluable clinical tool allowing the delivery of therapeutic agents that are 
otherwise unsuitable for administration through oral routes but, the waste arising from the 
application of needles has long been a critical concern.  There have been extensive surveys cataloguing 
the experiences of health care workers and the hazards posed by the use and disposal of needles [1-
3]. In particular, the possibility of needlestick injury (NSI) has become an ever-present hazard within 
healthcare settings and estimated to account for 80% of percutaneous injuries [4]. It is little surprise 
therefore to find that most countries have imposed a variety of legislative requirements to promote 
the adoption of safe working practices. The US Needlestick Safety and Prevention Act (2000) and the 
Occupational Safety and Health Administration (OSHA) Bloodborne Pathogen (BBP) Standard (2001) 
are notable in that it has been estimated that the incidence of sharps injuries dropped by some 34% 
shortly after their introduction [5,6]. Despite such advances, the eradication of NSI continues to be 
elusive and there remains considerable concern with an estimated 300,000 needlestick injuries 
reported annually in the US alone [7,8]. It must be noted that the true value is liable to be substantially 
higher as, it is widely acknowledged, many injuries go unreported [9]. A breakdown of NSI incidence 
by the Centres for Disease Control and Prevention [4], summarised in Figure 1, highlight that NSI 
events tend to fall within three main categories: during the procedure (40%), after use but before 
disposal (15%) and during disposal (40%).  
A crucial aim of the regulatory instruments was to enhance safety through stipulating the mandatory 
provision of safety devices and sharps containers but, from the summary presented in Figure 1, it is 
clear that there is still some way to go in order to improve their efficacy. Advances in microneedle 
devices, typically in the form of patches, have garnered considerable interest in recent years as a 
potential alternative to hypodermic injections and are widely considered to possess a range of 
advantageous properties in relation to their clinical application [10,11]. While the needles are small, 
their ability to puncture the skin nevertheless renders them a potential sharps risk and their handling 
and disposal requires more than a modicum of caution. The latter is evidenced by a recent health 
notice from Public Health England (2017) highlighting concern over the use of microneedle rollers used 
in cosmetic practice[12]. Although it has been estimated that there are some 60 blood borne 
pathogens, the majority of occupation related infections are attributed to hepatitis B virus (HBV), 
hepatitis C virus (HCV) and human immunodeficiency virus (HIV) [13,14]. Upon penetrating the skin, 
the microneedles will be in contact with the subject’s tissue and microcirculation, with the subsequent 
removal of the patch risking the retrieval of blood and/or serous fluid. Given the potential translation 
of microneedle systems to HHC contexts, it is vital therefore that the risk of accidental application and 
transmission of a BBP through carless use or disposal be acknowledged. The aim of this mini-review is 
to examine the present state of play in terms of sharp waste within both clinical and home health care 
environments and to provide a critical appraisal of the potential opportunities that microneedle 
devices proffer for reducing NSI events. There has been increasing interest in the latter in recent years 
and the technology is now at the point where there have been considerable advances in the design 
that could have far reaching consequences in terms of handling and waste management. 
 
Figure 1. Incidence of needlestick injuries by device type (A), process (B), person (C) and location(D). 
(Figures adapted from Reference 4.) 
2.0 Home Health Care  
Needlestick injuries are not confined to clinical settings however and it is within community and home 
health care that the hazards are becoming more apparent [15,16]. The increasing devolution and 
decentralisation of healthcare towards community care has meant that the management of many 
conditions is conducted within the home either by community nurses or by the patients themselves. 
Recent estimates suggest that there are some 3 million home healthcare workers in the US alone [17-
21] and, with an annual impact of some $70 bn [20,21] is widely recognised as one of the fastest 
growing industries. The majority of HHC workers are classified as personal care assistants or home 
aides and, while their job specification may detail non-medical tasks [17-19], numerous surveys have 
highlighted the expansion of their role to assist with lancets or needles [22,23]. It is widely recognised 
that people are living longer with chronic conditions such as HIV and hepatitis and are receiving care 
in the home more frequently. As such, the potential for transmission of a BBP through accidental NSI 
is greatly increased [24]. The increasing concern is highlighted by reports that 35% of nurses and 6% 
of aides suffered at least one injury with a previously used sharp during their HHC career and that 
SEDs were uncommon[16]. 
The improvements that have been achieved thus far in reducing NSI incidence have come through 
professional responsibility and institutional accountability and, while OSHA standards still apply to 
treatment supplied by community care nurses, such frameworks are largely absent when considering 
patient led treatment. It is inevitable that many will involve the use of parenteral injections 
(intravenous, subcutaneous or intramuscular) and creates a degree of concern over the methods of 
waste disposal and the accompanying sharps hazard. In the US, there are some 9 million patients 
receiving some form of healthcare at home that requires self-injection and, given an estimated 3 
billion used sharps are regularly disposed of outside institutional frameworks with many HHC patients 
placing potentially contaminated sharps in the domestic waste [25]. The general approaches to waste 
disposal for Community Healthcare Practitioner Led and Patient Led sharps management are 
compared in Figure 2. 
 
 Figure 2. Sharps disposal practices for Healthcare worker and patient managed treatment regimes 
 
The disposal procedure for sharp wastes within clinical settings and by community nurses follow a 
well-regulated pathway whereby the filled containers are removed, at least in principle, by 
experienced waste contractors. Needle use and disposal by self-injecting patients is however more 
complex and is subject to a myriad of human attitudes and perceptions in combination with logistical 
factors. There are obvious detractors such as the need to procure the sharps container and to return 
it to a designated collection facility and there will be inevitable issues over costs associated with the 
supply and transport of the container. It is also likely that a proportion of patients may simply dismiss 
the seriousness of the sharp hazard.  
A worrying trend that has arisen among the diabetic community however, is for the reuse of insulin 
needles and lancets despite warnings over the possibility of infection and the fact that each use leads 
to the mechanical deformation of the needle tip which increases tissue scarring (lipodystrophy) and 
can increase the risk of metallic fracture and fragments being left in the skin [26].  A survey by Costello 
and colleagues found that when interviewing diabetic patients on their approach to sharps waste – 
86% did not follow the proper procedure with the majority simply placing discarded needles within 
the household trash [27]. Furthermore, 7% disposed of their waste needles by means of the toilet. The 
fact that the needles are placed within normal plastic bags ill-equipped to deal with potential needle 
puncture or are flushed to waste presents clear hazards for the workers collecting the domestic waste 
or dealing with sewer drainage or downstream water treatment [27].   
 
3.0 Engineering a Solution to Needlestick Injuries 
The provision of safety engineered devices(SEDs) to improve sharps safety has been widely advocated 
as a means through which to safeguard against potential injury [5] and there is no doubt that the 
introduction of needle enclosures that disarm the sharp (through retracting, sheathing or blunting) 
combined with the increased accessibility of sharps containers have played a significant part in 
reducing the incidence of injury within the workplace [1,2]. Yet, it would appear, at least on the basis 
of the CDC figures, that disposal accounts for some 60% of NSI events [4]. More worrying is the fact 
that a significant proportion (5%) of NSIs arise through enacting the disarming mechanism that is 
intended to render the sharp safe. The results of the Massachusetts NSI surveillance study (2007) 
found that, of those subject to injury, 65% did not use any needle safety device and, of the 31% that 
did, 28% cited device failure among the causative factors [3]. A survey of community nurses by Quinn 
and coworkers (2009) found a variety of negative attitudes towards the safety devices where they 
were perceived to be too difficult to use (26%), did not work well (24%) and were generally too time 
consuming to apply (7%)[16]. It is clear from many similar reports that there is still a considerable need 
for the design of more effective and accessible safety solutions. 
 
4.0  The Quest for Needle Free Delivery   
The introduction of needle free transdermal delivery systems has long been the aspiration but it has 
become more of a reality in recent years. Microneedle technologies in particular have risen to the fore 
and have captured the attention of the healthcare community as they profess to eliminate the issues 
of needle phobia but, more importantly, counter a raft of safety issues normally associated with 
needle disposal. Microneedle systems are designed to puncture the outer skin layers and allow 
passage of a drug directly through to the underlying microcirculation [28]. These tend to have an array 
of micron sized projections (50-900 m long) as highlighted in Figure 3. The needles typically need to 
be of a minimum length in order to overcome the elastic deformation of the epidermis. This was 
demonstrated by Verbaan and co-workers (2007) where movement of the skin during the 
application/insertion of the microneedle patch composed of 300 micron needles failed to puncture 
the skin barrier[29]. In general, the actual penetration depth is markedly less than the overall length 
of the actual microneedle.  
 
Figure 3.  A) Comparison of a microneedle patch (200x200x350 m) with a standard hollow-bore needle.        
B) Electron micrograph of the polystyrene microneedle patch. 
 
4.1 Microneedle Designs & Implications 
The central rationale behind the development of microneedles as a delivery system arose from the 
desire to offer pain free administration, associated with transdermal routes, whilst creating 
microchannels that breach the hydrophobic skin barrier and thereby enable a far greater range of 
drugs to be transported [30,31]. Recent investigations of user perceptions and direct experience of 
microneedle patches found that the majority of those surveyed described their application as a 
‘pressing,’ or ‘heavy’ sensation in comparison to the ‘sharp’ and ‘stabbing’ feeling arising from 
conventional hypodermic injection [32]. Studies, comparing the skin sensation of applying a flat 
baseplate with that of a microneedle patch, found that only 20% of the volunteers were able to 
distinguish between the two and confirmed that while the needles are generally sufficiently short to 
avoid activation of the underlying dermal nerve network [33].  There are five basic approaches 
commonly used in the design of microneedle drug delivery systems and are based on: solid, coated, 
hollow, dissolvable and swellable designs. The mode of action for each design rationale is summarised 
in Figure 4 and the features and safety issues associated with each described briefly within the 
following sections.  
 
Figure 4. Mode of action inherent to solid (A), coated (B), hollow(C), dissolvable(D) and swellable (E) 
microneedle systems. 
Irrespective of the administration route, the mode of operation the physical damage to the skin is 
minimal as a consequence of the small dimensions of the needles and, under non-occlusive conditions, 
the channels close within 2 hours of the original treatment [34]. It has been shown however that the 
lifetime of the micropore can be extended through chemical manipulation where the introduction of 
diclofenac and fluvastatin as co-eluting drugs can delay closure by up to 7 days [35,36]. It has been 
postulated that the resulting microchannels, and any delay in closure, could effectively serve as a 
highway to the underlying tissue and microcirculation for bacteria. It can be anticipated that the 
implementation of good clinical practice (i.e. swabbing the area with antibacterial wipes such as 
alcoholic chlorhexidine etc.) prior to exposure can often preclude the influx of adventitious species 
that may be present on the surrounding skin. A number of studies however have demonstrated that 
the potential for infection arising from microneedle application is considerably less when compared 
with conventional injection systems [37,38]. Advances in polymer processing have also seen the 
development of needles that possess an intrinsic antibacterial action which can further reduce the 
threat of infection from microbes that may have been inadvertently drawn into the channel during 
application of the patch [39]. Despite such innovations, the potential transmission of BBP as a 
consequence of accidental puncture still remains. 
 
4.2 Solid Microneedles / Coated Microneedles 
Solid microneedles based on silicon, titanium or stainless steel were among the first to be investigated 
for use within drug delivery systems whereby the needles are applied to the skin through a discrete 
patch, or by mean of a punch or roller are commonly referred to as “poke and patch” approaches [40].  
Such systems are similar to the dermabrasion rollers used in cosmetic treatments which have received 
interest from regulators concerned with the transmission of BBP. More recent designs however have 
focused on coating the needle arrays with a therapeutic agent [41]. Once the patch is applied, the 
needles breach the SC layer allowing the drug molecules to simply dissolve into the surrounding tissue 
and diffuse to the microcirculation. The dosage transferred ultimately depends on the microneedle 
area onto which the drug can be coated and therefore the potential yield will be limited. The use of 
coated microneedles has however found a particular niche in the delivery of agents with a low yield-
high potency profile (ie. antigenic material / RNA) [42]. The exploitation of microneedles as a vaccine 
delivery system is particularly pertinent as there is a significant population of antigen presenting cells 
(APCs) within the outer skin layers which enables a strong immune response to be obtained from the 
delivery of small amounts of immunogenic material [43]. Ahmad and coworkers (2015) have critically 
reviewed the various processes through which the microneedles can be coated to optimise the 
delivery yield [44] 
It has been shown that the microneedle approach in such contexts results in comparable or, in some 
cases, superior performance to conventional subcutaneous and intramuscular injections [45-46]. 
Crucially, the approach deftly avoids many of the safety concerns associated with conventional 
hypodermic needles and avoids issues of patient needle phobia. The latter can be especially important 
when considering the vaccination of young children and there have been numerous studies comparing 
the preference of patch to conventional needle systems. An interesting note is that it has been 
postulated that self-administered patches could improve vaccination uptake. This assertion has been 
supported in a recent study where the availability of the latter was found to increase intent to be 
vaccinated from 44% to 65% when compared with the standard injection modes [47,48]. 
4.3 Hollow Microneedles 
Hollow microneedles have been developed to allow the transfer of the drug from a reservoir within 
the patch to the microcirculation and can enable volumes of up to 200 L to be transported and, in 
many respects, the system mimics the operation of a conventional hypodermic syringe [43, 49-52]. It 
must be noted that hollow needle fabrication is significantly more complex and those possessing a 
high aspect ratio lack the internal support structure common to solid needles leading to potential 
failure if improperly inserted. It can be expected that random movements during manipulation of the 
patch assembly or device, during both insertion and removal, which will result in a variety of stresses 
(axial compression and sheer) which may lead to the failure and fracture of the needles [53-57]. The 
latter can be significantly complicated by natural variations in morphology of the patient’s skin where 
non-uniform insertion of the microneedle array will inadvertently induce sheer stress and cause 
transverse bending of the microneedle structures [58,59]. Most approaches to the manufacture of 
microneedles acknowledge that a decrease in the microneedle height counters many of structural 
stress issues and provides a more favourable safety margin [58].  
4.4 Dissolvable & Swellable Microneedles 
One of the more recent strategies to emerge in microneedle design is based on the use of dissolvable 
polymers. The rationale here that drug to be delivered is entrapped within the core of the needle at 
the time of fabrication. Upon breaching the skin, the polymer that forms the architecture of needle 
dissolves and thereby releases a drug. The dissolution of the needle within the skin effectively 
eliminates the possibility of post application NSI [60-67].  As with coated solid microneedles, a core 
restriction relates to the delivery yield as the primary drug delivery component is the needle structure 
and, unlike the hollow needle designs, the base plate does not normally act as a reservoir [28]. This 
introduces a degree of complexity in the manufacture as there must be a balance between the amount 
of drug to be delivered and the amount of polymer required to ensure the structural integrity of the 
actual needle [59]. Liu and co-workers (2014) found that in the case of insulin, the maximum drug 
content was around 10% giving a delivery yield of 0.6 mg per cm2 [67].   
Microneedles that swell after puncturing the stratum corneum are a further refinement and aim to 
address the low yield restrictions of the dissolvable designs. The patches are based on a hydrogel 
structure whose hydrophilicity actively absorbs fluid from the surrounding tissue resulting in an 
expansion of the needle core creating pores and nano-channels through which the therapeutic agent 
can diffuse [42]. A core advantage of this approach centres on the use of the baseplate as a reservoir 
for the drug which is capable of transport through the swollen microneedle structure to the underlying 
microcirculation.  Some of the more recent developments in dissolvable and swellable microneedle 
systems are highlighted in Table 1 and it can be seen that there is a wide variety of drug candidates 
and potential applications. A particularly innovative translation of the swellable system is the ability 
to extract interstitial fluid [78,80,83]. Given that most blood sampling involves IV extraction, the 
swellable MN system offers painless removal of fluid whilst the swollen needles removes the 
possibility of post sample needlestick.  
    Table 1. Recent developments in dissolvable/swellable microneedle systems 
Drug Polymer Type Ref 
Dihydroergotamine 
mesylate 
Polyvinylpyrrolidone D 68 
Thymopentin Polyvinylpyrrolidone D 69 
Exendin-4 Carboxymethylcellulose D 70 
Fluorescent Model Hyaluronic acid /PVA D 71 
Sumatriptan succinate Polyvinylpyrrolidone D 72 
Adenosine Hyaluronic acid D 73 
Vitamin K 
Gantrez® S-97, a copolymer of 
methyl vinyl ether and maleic 
acid 
D 74 
Lysozyme Polyvinylpyrrolidone D 75 
Valproic acid Carboxymethylcellulose D 76 
Besifloxacin Polyvinylpyrrolidone D 77 
Caffeine / Theophylline 
 
Hydrolysed poly(methyl-vinyl 
ether-co-maleic anhydride) and 
poly(ethyleneglycol) 
 
S-E 78 
None Specified 
 
Poly (methyl vinyl ether-co-
maleic acid) and pectin  
 
S 79 
Glucose/ Cholesterol 
 
Methacrylated hyaluronic acid 
 
S-E 80 
FITC-dextrans 
 
Silk fibroin 
 
S 81 
Curcumin 
Gantrez® S-97poly(methyl vinyl 
ether-co-maleic acid) and Tween 
85 
S 82 
    Where: D = dissolving; S = swellable; S-E = swellable extraction of fluid 
 
The time taken from skin puncture to channel closure has been shown to be of the order of several 
hours for conventional, solid needles but the situation can become more complex with the 
dissolvable/swellable systems in situations where undissolved polymer residues may be left behind 
and continue to transcend the skin barrier. There can be little doubt that rapid healing of the puncture 
microchannels will be a major factor in minimising infection but this could be compromised where 
there is a failure in the dissolution or removal of a swellable microneedle. There is scant information 
available on the mechanical failure of such systems and the consequences for restoring skin integrity 
but this reflects the fact that research within this particular niche is only just emerging. The emphasis 
is still on the technological advances inherent in the design and material functionality and it is 
inevitable that the implications for skin function will begin to emerge in the future. 
5.0 Needle Handling and Disposal 
The disposal of sharps has been a perennial safety issue even within standard, well regulated, 
environments [84]. On a local level, sharps collection containers are undoubtedly the most visible 
example of safety control measure but their effectiveness in minimising injury however resides on the 
responsibility of the user to comply with good practice [15]. Sadly, their misuse has led to the 
recognition of “container associated sharps injury” (CASI) as a new hazard category and, presently, it 
is estimated that it, alone, accounts for 5-6% of annual sharps injuries [85]. Most recorded incidents 
are attributed to being struck by the sharp being disposed at the time (53%) or from sharps that 
protrude from the container opening for reasons other than over filling (33%) and, in most cases, the 
causative factor is largely carelessness in the disposal process [8, 27, 85]. On a local level, where there 
is a need for repeated injection (i.e. insulin), the frequency and associated bulk means that there will 
be a corresponding increase in the frequency with which sharps containers must be replaced and, 
particularly from a Home Health Care perspective, can be a reason for over filling and hence accidental 
NSI. Difficulties with procuring a container, facilitating its removal and the associated costs are 
significant factors in the failure to observe appropriate safety measures and leads to disposal through 
the domestic trash.  
Blenkharn and Odd (2008) conducted a detailed analysis of a specialist waste contractor and found 
that most issues (85%) arise where there is inadequate segregation of soft wastes (dressings etc) from 
sharps[86]. They found that the latter invariably end up in thin plastic refuse sacks that afford no 
puncture protection to the housekeeping staff and waste handlers with the incomplete closure of the 
sharps containers accounting for the remainder (15%). The main cause of injury was attributed to 
hypodermic syringes (92.5%) with puncture wounds being the most common. The overall incident rate 
was 1 per 29,000 man hours but this was for an organisation with employees well versed in the hazards 
associated with medical waste with access to appropriate personal protection equipment (PPE). A 
study by Turnberg (1996) reported that in USA, workers handling clinical waste had a 2.4–7 times more 
chance of getting infected by HIV compared to other staff in healthcare facilities [87]. The hazard is 
compounded by the cost associated with the treatment and disposal of medical waste whereby the 
latter can be prone purposeful misclassification and improper disposal [88-90]. It has been estimated 
that general waste costs some 10-20 times less to dispose of than clinical waste [90]. 
It must be noted from the investigation by Blenkharn and Odd that a prime contributor to the 
subsequent injury was the failure of the employee to apply the correct PPE [86]. When considering 
domestic trash originating from Home Health Care, it is likely that the movement from house waste 
bin to external collection bin will be conducted by a family member or helper who will be unprepared 
should there be the possibility of a NSI. Skin puncture from a protruding needle will clearly raise the 
possibility of BBP but the significance of the injury may be lost and, as such, there may well be no 
serological testing nor post exposure prophylaxis. Given that speed is crucial in the application of the 
latter, the consequences of a delay in follow up could be life threatening. Likewise, there will be latent 
risk for those municipal workers handling the collection of the waste [91,92]. Microneedle patches, 
particularly those based on dissolvable/swellable designs would clearly avoid many of the issues 
associated with conventional needle disposal and as the sharp component is largely removed at the 
time of application – would effectively eliminate the threat of subsequent NSI and the transmission of 
a BBP. 
It is also important to rationalise the impact of the microneedle system on the volume of the waste. 
In principle, it would remove the need for specialised sharps containers (thereby removing CASI) and, 
in principle, would enable the disposal in general waste. The latter has increasing significance where 
the volume of waste associated with conventional sharps and it segregation into specialised categories 
creates a considerable economic burden for healthcare administrators. An example of the magnitude 
is given by Emmanuel and colleagues (2004) in which it was reported that a relatively small vaccination 
campaign in the Philippines gave rise to over 130 tonnes of sharps waste [93]. It must also be noted 
that in less developed countries, the disposal of medical waste onto municipal sites will also 
dramatically increase the risk of NSI where scavenging occurs and it is not uncommon for the recycling 
of the medical wastes [91,94]. The use of microneedle patches in removing the NSI threat in such 
contexts cannot be overstated. 
It is hard to envisage any threat from the microneedle but that perception, in itself, can be hazardous.  
There is an increasing interest in the use of microneedle systems for diagnostics [95] which will 
inevitably be based on solid, non dissolvable systems. As such, they can still constitute a sharps hazard 
much in the same way that dermarollers have given rise to caution [12]. The removal of a patch in 
which the needle array is still intact could present a hazard for BBP transmission. Moreover, as there 
is little or no sensation upon microneedle puncture, there may be no recognition that a NSI has taken 
place and, as such, there will be no follow up investigation, treatment or counselling. It must be 
appreciated however that the actual risk of BBP from a microneedle patch will be very limited. The 
transmission of a BBP from a hollow-bore syringe needle has been estimated to be some ten times 
greater than through contact with a solid needle (i.e. a suture needle). The disparity here relates 
primarily to the smaller volume held by the solid surface [96,97]. Clearly, the area of the microneedle 
in contact with the tissue will be very small and thus the liquid holding capacity (at least in terms of 
solid microneedle) will be very small.  
 
6.0 Conclusions 
Microneedle patches have evolved as an alternative to conventional hypodermic injections in a 
number of clinical applications largely on the basis that they can offer pain free drug delivery that 
counters the apprehension that conventional hollow bore needles generate. The latter is particularly 
pertinent when considering paediatric vaccinations where the more “Velcro” like perception of the 
needle patch can help dispel anxiety and actually enhance participation. It is clear that microneedles 
possess enormous promise and could radically reduce the potential for needlestick injury. There 
remain many challenges in microneedle design – especially in relation to drug yield and, while the 
devices cannot completely replace conventional hollow-bore needles, they have the capability of 
making significant in-roads in drug delivery practice  
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